281 related articles for article (PubMed ID: 35891421)
1. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients.
Franchini M; Focosi D; Percivalle E; Beccaria M; Garuti M; Arar O; Pecoriello A; Spreafico F; Greco G; Bertacco S; Ghirardini M; Santini T; Schiavulli M; Stefania M; Gagliardo T; Sammartino JC; Ferrari A; Zani M; Ballotari A; Glingani C; Baldanti F
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891421
[TBL] [Abstract][Full Text] [Related]
2. High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge.
Tayyar R; Wong LK; Dahlen A; Shu E; Pandey S; Liu AY
Transpl Infect Dis; 2023 Apr; 25(2):e14055. PubMed ID: 36929619
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors.
Franchini M; Focosi D; Mengoli C; Percivalle E; Sammartino JC; Ferrari A; Zani M; Glingani C; Baldanti F
Transfusion; 2022 Jun; 62(6):1171-1176. PubMed ID: 35426131
[TBL] [Abstract][Full Text] [Related]
4. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources.
Sullivan DJ; Franchini M; Joyner MJ; Casadevall A; Focosi D
Nat Commun; 2022 Oct; 13(1):6478. PubMed ID: 36309490
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study.
Bartelt LA; Markmann AJ; Nelson B; Keys J; Root H; Henderson HI; Kuruc J; Baker C; Bhowmik DR; Hou YJ; Premkumar L; Cornaby C; Schmitz JL; Weiss S; Park Y; Baric R; de Silva AM; Lachiewicz A; Napravnik S; van Duin D; Margolis DM
mBio; 2022 Oct; 13(5):e0175122. PubMed ID: 36135380
[TBL] [Abstract][Full Text] [Related]
6. Are convalescent plasma stocks collected during former COVID-19 waves still effective against current SARS-CoV-2 variants?
Focosi D; Franchini M; Joyner MJ; Casadevall A
Vox Sang; 2022 May; 117(5):641-646. PubMed ID: 35023163
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes.
Yokoyama APH; Wendel S; Bonet-Bub C; Fachini RM; Dametto APF; Blumm F; Dutra VF; Candelaria GTP; Sakashita AM; Machado RRG; Fontão-Wendel R; Hamerschlak N; Achkar R; Assunção MSC; Scuracchio P; Nudelman V; Pastore L; Pinho JRR; Ben MD; Filho RK; Marra AR; Amano MT; Kallás EG; Helito AS; de Carvalho CRR; Araujo DB; Durigon EL; Camargo AA; Rizzo LV; Reis LFL; Kutner JM
Transfusion; 2021 Aug; 61(8):2295-2306. PubMed ID: 34173248
[TBL] [Abstract][Full Text] [Related]
8. Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies.
Jazbec K; Jež M; Žiberna K; Mali P; Ramšak Ž; Potokar UR; Kvrzić Z; Černilec M; Gracar M; Šprohar M; Jovanovič P; Vuletić S; Rožman P
Virol J; 2023 Mar; 20(1):53. PubMed ID: 36973781
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19.
Sanz C; Nomdedeu M; Pereira A; Sauleda S; Alonso R; Bes M; Brillembourg H; García-Vidal C; Millan A; Martínez-Llonch N; Pirón M; Puerta-Alcalde P; Puig L; Rico V; Soriano A
Transfusion; 2022 May; 62(5):974-981. PubMed ID: 35338710
[TBL] [Abstract][Full Text] [Related]
10. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
11. Reduced neutralizing antibody potency of COVID-19 convalescent vaccinated plasma against SARS-CoV-2 Omicron variant.
Gallian P; Amroun A; Laperche S; Le Cam S; Brisbarre N; Malard L; Nurtop E; Isnard C; Richard P; Morel P; Tiberghien P; de Lamballerie X
Vox Sang; 2022 Jul; 117(7):971-975. PubMed ID: 35577569
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.
Bar KJ; Shaw PA; Choi GH; Aqui N; Fesnak A; Yang JB; Soto-Calderon H; Grajales L; Starr J; Andronov M; Mastellone M; Amonu C; Feret G; DeMarshall M; Buchanan M; Caturla M; Gordon J; Wanicur A; Monroy MA; Mampe F; Lindemuth E; Gouma S; Mullin AM; Barilla H; Pronina A; Irwin L; Thomas R; Eichinger RA; Demuth F; Luning Prak ET; Pascual JL; Short WR; Elovitz MA; Baron J; Meyer NJ; Degnan KO; Frank I; Hensley SE; Siegel DL; Tebas P
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34788233
[TBL] [Abstract][Full Text] [Related]
13. Convalescent plasma in hospitalized pediatric and obstetric coronavirus disease 2019 (COVID-19) patients.
Ikeda S; Benzi E; Hensch LA; Devaraj S; Hui SR; Gandhi M; Fox KA; Teruya J; Munoz FM
Pediatr Int; 2022 Jan; 64(1):e15407. PubMed ID: 36326636
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of COVID-19 convalescent plasma donors increases binding and neutralizing antibodies against SARS-CoV-2 variants.
Di Germanio C; Simmons G; Thorbrogger C; Martinelli R; Stone M; Gniadek T; Busch MP
Transfusion; 2022 Mar; 62(3):563-569. PubMed ID: 35129839
[TBL] [Abstract][Full Text] [Related]
15. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
16. COVID 19 convalescent plasma: Is there still a place for CCP?
Moog R
Transfus Apher Sci; 2023 Apr; 62(2):103680. PubMed ID: 36870907
[TBL] [Abstract][Full Text] [Related]
17. Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme-The South African Experience.
Glatt TN; Hilton C; Nyoni C; Swarts A; Swanevelder R; Cowley J; Mmenu C; Moyo-Gwete T; Moore PL; Kutama M; Jaza J; Phayane I; Brits T; Koekemoer J; Jentsch U; Nelson D; van den Berg K; Vermeulen M
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696480
[TBL] [Abstract][Full Text] [Related]
18. Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be?
Wendel S; Fachini R; Fontão-Wendel RCL; Mello R; Velasquez CV; Machado RRG; Brito MA; Amaral M; Soares CP; Achkar R; Scuracchio P; Miyaji SC; Erdens MS; Durigon EL
Transfusion; 2021 Dec; 61(12):3455-3467. PubMed ID: 34674284
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
20. Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial.
Park HS; Yin A; Barranta C; Lee JS; Caputo CA; Sachithanandham J; Li M; Yoon S; Sitaras I; Jedlicka A; Eby Y; Ram M; Fernandez RE; Baker OR; Shenoy AG; Mosnaim GS; Fukuta Y; Patel B; Heath SL; Levine AC; Meisenberg BR; Spivak ES; Anjan S; Huaman MA; Blair JE; Currier JS; Paxton JH; Gerber JM; Petrini JR; Broderick PB; Rausch W; Cordisco ME; Hammel J; Greenblatt B; Cluzet VC; Cruser D; Oei K; Abinante M; Hammitt LL; Sutcliffe CG; Forthal DN; Zand MS; Cachay ER; Raval JS; Kassaye SG; Marshall CE; Yarava A; Lane K; McBee NA; Gawad AL; Karlen N; Singh A; Ford DE; Jabs DA; Appel LJ; Shade DM; Lau B; Ehrhardt S; Baksh SN; Shapiro JR; Ou J; Na YB; Knoll MD; Ornelas-Gatdula E; Arroyo-Curras N; Gniadek TJ; Caturegli P; Wu J; Ndahiro N; Betenbaugh MJ; Ziman A; Hanley DF; Casadevall A; Shoham S; Bloch EM; Gebo KA; Tobian AA; Laeyendecker O; Pekosz A; Klein SL; Sullivan DJ
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38483534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
